Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 3, 2017, Pages 533-542

  Brogan, Anita J ^a   Talbird, Sandra E ^a   Davis, Ashley E ^a   Thommes, Edward W ^b,c,e   Meier, Genevieve ^d,f  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d GSK   (Belgium)

^e Takeda Canada Inc   (Canada)

^f BD Technologies   (United States)

Author keywords

cost effectiveness analysis; dynamic transmission model; influenza; quadrivalent influenza vaccine; trivalent influenza vaccine; United States

Indexed keywords

INFLUENZA VACCINE;

AGE DISTRIBUTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYNAMIC TRANSMISSION MODEL; HEALTH CARE COST; INFLUENZA VACCINATION; MODEL; QUALITY ADJUSTED LIFE YEAR; SEASONAL INFLUENZA; VALIDATION STUDY; VIRUS INFECTIVITY; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGED; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; UNITED STATES; UTILIZATION; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 85012915756     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1242541     Document Type: Article

References (57)

1. Centers for Disease Control and Prevention (CDC). Influenza (Flu):Seasonal Influenza Q&A. Available at http://www.cdc.gov/flu/about/qa/disease.htm (accessed 12October2015)
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/jama.289.2.179
4. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US:measuring disease burden and costs. Vaccine 2007; 25:5086-96; PMID:17544181; http://dx.doi.org/10.1016/j.vaccine.2007.03.046
5. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64:818-25; PMID:26247435; http://dx.doi.org/10.15585/mmwr.mm6430a3
6. Jain VK, Rivera L, Zaman K, Espos RA, Jr., Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013; 369:2481-91; PMID:24328444; http://dx.doi.org/10.1056/NEJMoa1215817
7. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012; 8:CD004879; PMID:22895945
8. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7:CD001269; PMID:20614424; http://dx.doi.org/10.1002/14651858.CD001269.pub4
9. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2:CD004876; PMID:20166072; http://dx.doi.org/10.1002/14651858.CD004876.pub3
10. Verani JR, Irigoyen M, Chen S, Chimkin F. Influenza vaccine coverage and missed opportunities among inner-city children aged 6 to 23 months:2000–2005. Pediatrics 2007; 119:e580-6; PMID:17332178; http://dx.doi.org/10.1542/peds.2006-1580
11. Singleton JA. Influenza vaccination distribution and coverage, United States, 2010-11 and 2011-12 seasons. Available at http://www.cdc.gov/flu/pdf/fluvaxview/Singleton_Influenza_ACIP26Oct2011.pdf (accessed on 14October2015).
12. Centers for Disease Control and Prevention (CDC). Self-reported influenza vaccination coverage trends 1989–2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Available at http://www.cdc.gov/flu/pdf/professionals/nhis89_08fluvaxtrendtab.pdf (accessed on 14October2015)
13. Centers for Disease Control and Prevention (CDC). Estimated influenza vaccination coverage among adults and children–United States, September 1, 2004–January 31, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:304-7; PMID:15800475
14. Centers for Disease Control and Prevention (CDC). 2010-11 through 2013-14 State, regional, and national vaccination trend report. Available at http://www.cdc.gov/flu/fluvaxview/reports/reporti1314/trends/index.htm, accessed 12October2015.
15. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81-8; PMID:22252006; http://dx.doi.org/10.4161/hv.8.1.17623
16. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014; 10:1171-80; PMID:24609063; http://dx.doi.org/10.4161/hv.28221
17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276:1253-8; PMID:8849754; http://dx.doi.org/10.1001/jama.1996.03540150055031
18. Nwachukwu BU, Bozic KJ. Updating cost effectiveness analyses in orthopedic surgery:resilience of the $50,000 per QALY threshold. J Arthroplasty 2015; 30(7):1118-20.
19. TRADING Economics. United States GDP per capita 1960-2016. Available at http://www.tradingeconomics.com/united-states/gdp-per-capita (accessed on 11 January 2016)
20. World Health Organization. Cost-effectiveness thresholds. Available at http://www.who.int/choice/costs/CER_thresholds/en/, accessed 13October2015.
21. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M. Dynamic transmission modeling:a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health 2012; 15:828-34; PMID:22999132; http://dx.doi.org/10.1016/j.jval.2012.06.011
22. Thommes EW, Chit A, Meier GC, Bauch CT. Examining Ontario's universal influenza immunization program with a multi-strain dynamic model. Vaccine 2014; 32:5098-117; PMID:25024113; http://dx.doi.org/10.1016/j.vaccine.2014.06.005
23. Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis 2014; 14:365; PMID:24993051; http://dx.doi.org/10.1186/1471-2334-14-365
24. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK:a lifetime multi-cohort model. PLoS One 2014; 9:e98437; PMID:24905235; http://dx.doi.org/10.1371/journal.pone.0098437
25. Meier G, Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly:an updated analysis in the UK. J Med Econ 2015; 18:746-61; PMID:25903831; http://dx.doi.org/10.3111/13696998.2015.1044456
26. Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model. PLoS One 2015; 10:e0133606; PMID:26222538; http://dx.doi.org/10.1371/journal.pone.0133606
27. You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis 2014; 14:618; PMID:25420713; http://dx.doi.org/10.1186/s12879-014-0618-9
28. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong–a decision analysis. Hum Vaccin Immunother 2015; 11:564-71; PMID:25714506; http://dx.doi.org/10.1080/21645515.2015.1011016
29. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine:a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013; 13:343; PMID:23883186; http://dx.doi.org/10.1186/1471-2334-13-343
30. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate:a phase III randomized controlled trial in children. J Infect Dis 2013; 208:544-53; PMID:23847058; http://dx.doi.org/10.1093/infdis/jit263
31. Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, Belongia EA. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons:2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6:37-43; PMID:21668663; http://dx.doi.org/10.1111/j.1750-2659.2011.00263.x
32. Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis 2007; 11:40-7; PMID:16678464; http://dx.doi.org/10.1016/j.ijid.2005.10.008
33. Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, Edmunds WJ. Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 2008; 168:1082-90; PMID:18801889; http://dx.doi.org/10.1093/aje/kwn220
34. United States Census Bureau. Population estimates:Intercensal estimates. Available at http://www.census.gov/popest/data/intercensal/index.html (accessed on November 2015)
35. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Mathews TJ. Births:final data for 2012. Natl Vital Stat Rep 2013; 62:1-87
36. Murphy SL, Xu J, Kochanek KD. Deaths:final data for 2010. Natl Vital Stat Rep 2013; 61:1-117; PMID:24979972
37. Centers for Disease Control and Prevention (CDC). Pediatric and adult influenza vaccine price list for 2014-2015. Available at http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html (accessed 4April2014).
38. The Essential RBRVS. A comprehensive listing of RBRVS values for CPT and HCPCS codes. Utah:Ingenix, Inc., 2014.
39. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006; 12:1548-58; PMID:17176570; http://dx.doi.org/10.3201/eid1210.051015
40. Bureau of Labor Statistics. Household Data Annual Averages Table 37:“Median weekly earnings of full-time wage and salary workers by selected characteristics”. Available at http://www.bls.gov/cps/cpsaat37.pdf (accessed 14October2015)
41. Prosser LA, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults:costs and cost effectiveness. Pharmacoeconomics 2008; 26:163-78; PMID:18198935; http://dx.doi.org/10.2165/00019053-200826020-00006
42. Prosser LA, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 2005; 3:18; PMID:15780143; http://dx.doi.org/10.1186/1477-7525-3-18
43. United States Department of Labor:Bureau of Labor Statistics. Databases, Tables & Calculators by Subject. Consumer Price Index - All Urban Consumers (Series Id:CUUR0000SAM; Not Seasonally Adjusted; Area:U.S. city average; Item:Medical care; 2013 annual average value). Available at http://data.bls.gov/timeseries/cuur0000SAM (accessed 3March2016)
44. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 2:CD004879; PMID:18425905; http://dx.doi.org/10.1002/14651858.CD004879.pub3.
45. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines:a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
46. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains:a systematic review and meta-analysis. BMC Med 2013; 11:153; PMID:23800265; http://dx.doi.org/10.1186/1741-7015-11-153
47. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ. Time lines of infection and disease in human influenza:a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-85; PMID:18230677; http://dx.doi.org/10.1093/aje/kwm375
48. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine 2008; 26:5321-30; PMID:18647634; http://dx.doi.org/10.1016/j.vaccine.2008.06.101
49. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 2008; 9:151-61; PMID:18201141; http://dx.doi.org/10.1517/14656566.9.2.151
50. Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients:results from a retrospective population-based study. Curr Med Res Opin 2007; 23:2961-70; PMID:17939881; http://dx.doi.org/10.1185/030079907X242520
51. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses:using national measures to create condition-specific values. Med Care 1998; 36:778-92; PMID:9630120; http://dx.doi.org/10.1097/00005650-199806000-00002
52. Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine 2009; 27:2251-7; PMID:19428839; http://dx.doi.org/10.1016/j.vaccine.2009.02.024
53. Ortega-Sanchez IR, Molinari NA, Fairbrother G, Szilagyi PG, Edwards KM, Griffin MR, Cassedy A, Poehling KA, Bridges C, Staat MA. Indirect, out-of-pocket and medical costs from influenza-related illness in young children. Vaccine 2012; 30:4175-81; PMID:22546332; http://dx.doi.org/10.1016/j.vaccine.2012.04.057
54. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York:Oxford University Press, 1996.
55. Vynnycky E, Edmunds WJ. Analyses of the 1957 (Asian) influenza pandemic in the United Kingdom and the impact of school closures. Epidemiol Infect 2008; 136:166-79; PMID:17445311
56. Truscott J, Fraser C, Hinsley W, Cauchemez S, Donnelly C, Ghani A, Ferguson N, Meeyai A. Quantifying the transmissibility of human influenza and its seasonal variation in temperate regions. PLoS Curr 2009; 1:RRN1125; PMID:20029663
57. Longini IM, Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159:623-33; PMID:15033640; http://dx.doi.org/10.1093/aje/kwh092